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Clostridium difficile infection (CDI) remains poorly con-
trolled in many European countries, of which several 
have not yet implemented national CDI surveillance. 
In 2013, experts from the European CDI Surveillance 
Network project and from the European Centre for 
Disease Prevention and Control developed a protocol 
with three options of CDI surveillance for acute care 
hospitals: a ‘minimal’ option (aggregated hospital 
data), a ‘light’ option (including patient data for CDI 
cases) and an ‘enhanced’ option (including microbio-
logical data on the first 10 CDI episodes per hospital). 
A total of 37 hospitals in 14 European countries tested 
these options for a three-month period (between 13 
May and 1 November 2013). All 37 hospitals success-
fully completed the minimal surveillance option (for 
1,152 patients). Clinical data were submitted for 94% 
(1,078/1,152) of the patients in the light option; informa-
tion on CDI origin and outcome was complete for 94% 
(1,016/1,078) and 98% (294/300) of the patients in the 
light and enhanced options, respectively. The workload 
of the options was 1.1, 2.0 and 3.0 person-days per 
10,000 hospital discharges, respectively. Enhanced 
surveillance was tested and was successful in 32 of the 
hospitals, showing that C. difficile PCR ribotype 027 
was predominant (30% (79/267)). This study showed 
that standardised multicountry surveillance, with the 
option of integrating clinical and molecular data, is a 
feasible strategy for monitoring CDI in Europe.
Introduction
After recognition of European outbreaks of Clostridium 
difficile infections (CDIs) associated with the emer-
gence of PCR ribotype 027/NAP1 in 2005, CDI sur-
veillance at country level was encouraged by the 
European Centre for Disease Prevention and Control 
(ECDC) [1]. In 2008, an ECDC-supported European CDI 
survey (ECDIS) identified large intercountry variations 
in incidence rates and distribution of prevalent PCR 
ribotypes, with the outbreak-related PCR ribotype 027 
being detected in 5% (range: 0–26) of the character-
ised isolates [2]. The surveillance period was limited to 
one month and the representation of European hospi-
tals was incomplete; however, this has been the only 
European (comprising European Union (EU)/European 
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Economic Area (EEA) and EU candidate countries) CDI 
surveillance study. The authors highlighted the need 
for national and European surveillance to control CDI. 
Yet, European countries were found to have limited 
capacity for diagnostic testing, particularly in terms of 
standard use of optimal methods and absence of sur-
veillance protocols and a fully validated, standardised 
and exchangeable typing system for surveillance and/
or outbreak investigation.
As of 2011, 14 European countries had implemented 
national CDI surveillance, with various methodologies 
[3]. National surveillance systems have since reported 
a decrease in CDI incidence rate and/or prevalence of 
PCR ribotype 027 in some European countries [4-8]. 
However, CDI generally remains poorly controlled in 
Europe [9], and PCR ribotype 027 continues to spread 
in eastern Europe [10-12] and globally [13].
In 2010, ECDC launched a new project, the European 
C. difficile Infection Surveillance Network (ECDIS-Net), 
to enhance surveillance of CDI and laboratory capac-
ity to test for CDI in Europe. The goal of ECDIS-Net was 
to establish a standardised CDI surveillance protocol 
suitable for application all over Europe in order to: (i) 
estimate the incidence rate and total infection rate of 
CDI (including recurrent CDI cases) in European acute 
care hospitals; (ii) provide participating hospitals with 
a standardised tool to measure and compare their own 
incidence rates with those observed in other partici-
pating hospitals; (iii) assess adverse outcomes of CDI 
such as complications and death; and (iv) describe the 
epidemiology of CDI concerning antibiotic susceptibil-
ity, PCR ribotypes, presence of tcdA, tcdB and binary 
toxins and detect new emerging types at local, national 
and European level.
The primary objectives of the present study were to: 
(i) test the pilot protocol for the surveillance of CDI in 
European acute care hospitals developed by ECDIS-Net 
(methodology, variables and indicators); (ii) assess 
the feasibility and workload of collecting the required 
hospital data, case-based epidemiological and micro-
biological data; and (iii) evaluate the quality of data 
collected, whether in the presence or absence of exist-
ing national CDI surveillance activities. A secondary 
aim was to assess the relationship between patient 
and microbiological characteristics and in-hospital 
outcome of CDI to confirm the added value of collect-
ing detailed epidemiological and microbiological data 
on CDI at European level.
Methods
Study protocol and definitions
A pilot protocol for the surveillance of CDI in European 
acute care hospitals was developed by ECDIS-Net par-
ticipants (epidemiologists and medical microbiologists 
from various European countries) and ECDC experts 
in 2012–13. The pilot protocol version 1.2 specified 
three options for surveillance: ‘minimal’, ‘light’ and 
‘enhanced’ [14]. In the minimal surveillance, aggre-
gated numerator and denominator data were gathered 
on all CDI cases. In the light surveillance, basic case-
based epidemiological data were included (e.g. age, 
sex, date of hospital admission and of CDI onset, CDI 
origin, recurrent CDI) on all CDI cases. In the enhanced 
surveillance, additional epidemiological data (e.g. 
comorbidities scored by the McCabe score [15] and 
the Acute Physiology and Chronic Health Evaluation 
II (APACHE II) chronic health points [16], in-hospital 
deaths) and C. difficile isolates were collected for the 
Figure 1
Data collection in the pilot study for standardised 
surveillancea of Clostridium difficile infection in 37 acute 
care hospitals in 14 European countriesb, 13 May–1 
November 2013c
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CDI: Clostridium difficile infection.
a Three surveillance options were tested: ‘minimal’ (aggregated 
hospital data), ‘light’ (including patient data for CDI cases) and 
‘enhanced’ (including microbiological data on the first 10 CDI 
episodes per hospital).
b Austria, Belgium, Denmark, Estonia, Finland, France, Germany, 
Hungary, the Netherlands, Norway, Poland, Romania, Serbia, 
United Kingdom (Scotland only). Enhanced surveillance including 
PCR ribotyping was carried out by Austria, Belgium, Finland, 
France, Germany, Hungary, the Netherlands, Norway, Poland and 
United Kingdom (Scotland only); Denmark, Romania and Serbia 
participated in enhanced surveillance, but did not perform PCR 
ribotyping at the national reference laboratory or appointed 
study laboratory.
c Three-month assessment during this time period.
d Clincial patient data missing, for reasons unknown.
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Figure 2
Incidence rate of healthcare-associated Clostridium difficile infection using ‘minimal’ surveillancea, by region (n = 22)b and 
distribution of PCR ribotypes identified using enhanced surveillance, by European country (n = 13)c, 13 May–1 November 
2013d
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CDI: Clostridium difficile infection; NUTS: nomenclature of territorial units for statistics.
The pilot study was based on a non-representative sample, thus the rates and distributions presented in this figure cannot be interpreted as being representative of any 
NUTS region.
a The ‘minimal’ surveillance option comprised aggregated hospital data; the ‘enhanced’ option included microbiological data on the first 10 CDI episodes per hospital.
b The NUTS 1 region indicates the geographical location of each participating hospital, rather than that of the hospital’s catchment area. The incidence rate per 10,000 
patient-days in each NUTS 1 region is the median for all hospitals that participated within that same region.
c The number of PCR ribotyped strains varied by country: Austria (34), Belgium (26), Denmark (38), Finland (10), France (9), Germany (28), Hungary (17), the Netherlands (27), 
Norway (18), Poland (16), Romania (13), Serbia (22) and United Kingdom (Scotland only) (9).
d Three-month assessment during this time period.
Source of map: FreeVectorMaps.com (http://freevectormaps.com).
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first 10 episodes of CDI per hospital. Outcome was not 
followed up after discharge from the hospital.
The case definitions for CDI (Box) were based on rec-
ommendations for CDI surveillance, as proposed by 
ECDC and the United States Centers for Disease Control 
and Prevention (CDC) [1,17].
Patients were included as a CDI case if symptom onset 
occurred within the hospitals’ surveillance period, or 
if the patient was admitted during the surveillance 
period with symptoms present. Infants (children below 
two years-old) with ‘compelling clinical evidence for 
CDI’ were also included.
Participants and study period
A total of 14 countries participated in this pilot study: 
they were selected by the project leaders given their 
various levels of ongoing surveillance activities and 
laboratory and typing capacity for CDI [18]. At the 
start of the ECDIS-Net project, nine countries (Austria, 
Belgium, Denmark, Finland, France, Germany, Hungary, 
the Netherlands and United Kingdom (Scotland only), 
hereafter referred to as UK-Scotland) had already 
implemented national surveillance of CDI; five coun-
tries (Estonia, Norway, Poland, Romania and Serbia) 
had not. ECDIS-Net participants identified a conveni-
ence sample of two to four acute care hospitals per 
country to test the pilot protocol for a three-month sur-
veillance period between 13 May and 1 November 2013. 
Hospitals were encouraged, but not obligated, to test 
all surveillance options in the protocol and to involve 
both hospital infection control personnel and microbi-
ology laboratory personnel in data collection. It was 
agreed that the actual location of participating hospi-
tals would not be disclosed for reasons of confidenti-
ality. We identified the proxy location of participating 
hospitals by mapping the median healthcare-associ-
ated CDI incidence rates obtained in this pilot study 
using the nomenclature of territorial units for statistics 
(NUTS) 1 regions [19] that contained at least one par-
ticipating hospital.
Microbiological investigation
Local laboratories that serviced the participating hos-
pitals used their own diagnostic procedures for CDI. 
Data on the algorithm used for CDI diagnosis was col-
lected for each patient included in light surveillance. 
In the enhanced surveillance option, 10 C. difficile iso-
lates (or stool samples, if there was no possibility of 
anaerobic culture at the local laboratory) from samples 
from the first 10 episodes of CDI per hospital were sent 
to the national reference laboratory or appointed study 
laboratory (collectively referred to as NRL) which per-
formed PCR ribotyping and antimicrobial susceptibility 
testing, performed according to national procedures. 
Most NRLs used conventional agarose gel-based 
PCR ribotyping [3] (Finland, France, Hungary, Poland, 
the Netherlands and UK-Scotland), some used capil-
lary-based PCR ribotyping [3] (Austria, Belgium and 
Germany). Denmark, Estonia, Romania and Serbia did 
not perform PCR ribotyping and for Norway, the PCR 
ribotyping method used was not reported. NRLs were 
requested to send all C. difficile isolates to the coor-
dinating laboratory (Leiden University Medical Centre, 
the Netherlands), which completed and confirmed 
microbiological results. The presence of a glutamate 
dehydrogenase (GDH) gene specific for C. difficile was 
confirmed in the coordinating laboratory by an in-house 
PCR [20], followed by PCR ribotyping [21]. Toxin genes 
(tcdA, tcdB, cdtA, cdtB) were detected by multiplex PCR 
[22]. In vitro susceptibility to metronidazole, vancomy-
cin, and moxifloxacin was determined by measuring 
minimum inhibitory concentrations (MICs) by an agar 
dilution method [23] and interpreted using epidemio-
logical cut-off values from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). Isolates 
with a metronidazole MIC > 2 mg/L, a vancomycin MIC > 2 
mg/L and moxifloxacin MIC > 4 mg/L were interpreted 
as resistant [24].
Data handling
Data were entered in a web-based system developed 
for the current study (by the Institute of Hygiene and 
Figure 3
Incidence rate of healthcare-associated Clostridium 
difficile infection in relation to the proportion of PCR 
ribotype 027 isolates, from ‘enhanced’ surveillancea in 
acute care hospitals in 13 European countriesb, 13 May–1 
November 2013c
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CA: community-associated; CDI: Clostridium difficile infection; CI: 
confidence interval; HA: healthcare-associated.
Whiskers indicate the 95% CI around the incidence rate of HA-
CDI per 10,000 patient-days per hospital. The proportion of 
PCR ribotype 027 isolates correlated with the incidence rate 
(Spearman’s rho: 0.64; 95% CI: 0.36–0.81).
a The ‘enhanced’ surveillance option included microbiological data 
on the first 10 CDI episodes per hospital.
b Austria, Belgium, Denmark, Finland, France, Germany, Hungary, 
the Netherlands, Norway, Poland, Romania, Serbia and United 
Kingdom (Scotland only).
c Three-month assessment during this time period.
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Environmental Medicine, Charité Universitätsmedizin 
Berlin, Germany, in 2013) and were analysed with SPSS 
version 20.0 and Stata software version 12.1.
Statistical analysis and study endpoints
Primary endpoints
Variables and indicators
For all variables in each surveillance option, frequen-
cies and proportions were calculated, as appropriate. 
Hospital median incidence rates for healthcare-asso-
ciated (HA) CDI and recurrent CDI were calculated per 
10,000 hospital discharges and per 10,000 patient-
days using minimal surveillance protocol data. 
Dispersion around the median was described with the 
25th and 75th percentile (interquartile range, IQR). We 
calculated 95% confidence intervals (CIs) for the inci-
dence rates by Byar’s approximation.
Feasibility and workload
Workload, defined as person-days per 10,000 hospi-
tal discharges required to complete each surveillance 
option, and feasibility were measured using a ques-
tionnaire distributed to all participants.
Data quality
Epidemiological data quality was primarily assessed 
by data completeness. This was estimated by compar-
ing each hospital’s minimal surveillance numerators 
(minimal option) with the number of available patient 
records (light option), and by calculating the pro-
portion of patients for whom origin of the CDI (light 
option) and course of infection (enhanced option) were 
recorded, with less than 10% missing data being con-
sidered acceptable.
Microbiological data quality was assessed through 
comparison of each hospital’s testing rate per 10,000 
patient-days and percentage of positive tests. 
Additionally, all NRLs’ ribotyping results obtained dur-
ing the pilot study were compared with those of the 
coordinating laboratory. Additionally, in May 2013 and 
September 2014, participation in two external quality 
assessments was offered by Public Health England to 
all ECDIS-Net NRLs that performed typing. NRLs in nine 
of the participating countries took part; on each occa-
sion, 10 C. difficile strains were sent to the same eight 
NRLs and the coordinating laboratory of this study.
Secondary endpoints
Relationships between the risk of a complicated course 
of CDI or all-cause in-hospital mortality in CDI cases (of 
any origin) and patient characteristics and microbiolog-
ical results (as confirmed by the coordinating labora-
tory) were analysed by logistic regression. Correlations 
between incidence rates, testing rates and the propor-
tion of PCR ribotype 027 were analysed by Spearman’s 
rank test.
Box
Definitions for surveillance of Clostridium difficile infections
CDI case 
A patient to whom one or more of the following criteria applies: 
1. diarrhoeal stools or toxic megacolon AND a positive laboratory assay for C. difficile TcdA and/or TcdB in stools or a toxin-
producing C. difficile organism detected in stool via culture or other means; 
2. pseudomembranous colitis revealed by lower gastrointestinal endoscopy; 
3. colonic histopathology characteristic of CDI (with or without diarrhoea) on a specimen obtained during endoscopy, 
colectomy or autopsy.
Recurrent CDI 
An episode of CDI (return of diarrhoeal stools with a positive laboratory test after the end of treatment) > 2 weeks and ≤ 8 
weeks following the onset of a previous episode (CDI cases with onset later than 8 weeks after the onset of a previous 
episode were included as new CDI cases).
Healthcare-associated case  
A case of CDI with onset of symptoms at least 48 hours following admission to a healthcare facility or with onset of 
symptoms in the community within 4 weeks following discharge from a healthcare facility.
Community-associated case 
A case of CDI with onset of symptoms outside a healthcare facility or within 48 hours after admission to a healthcare 
facility, without residence in/discharge from a healthcare facility within the previous 12 weeks.
Complicated course of CDI  
CDI leading to any of the following: 
1. admission to an intensive-care unit for treatment of CDI or its complications (e.g. for shock requiring vasopressor 
therapy); 
2. surgery (colectomy) for toxic megacolon, perforation or refractory colitis; 
3. death within 30 days after diagnosis if CDI is either a primary or contributing cause.
CDI : Clostridium difficile infection.
Source: [1,17].
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Reporting
This study was reported according to the Strengthening 
the Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines.
Results
Participating hospitals
A total of 37 acute care hospitals from 14 European 
countries tested the minimal and light surveillance 
options for a three-month period between 13 May 2013 
and 1 November 2013. Of the 37 acute care hospitals, 
21 were tertiary care hospitals, 10 secondary care hos-
pitals, five primary care hospitals and one was a spe-
cialised hospital for infectious and tropical diseases. 
A total of 36 hospitals included all wards; one hospi-
tal excluded a neonatal ward. Of the 37 participating 
hospitals, 32, from 13 countries, tested the enhanced 
option as well (Figure 1).
Minimal surveillance: incidence rate of Clostridium 
difficile infection
A total of 1,152 CDI episodes were recorded by minimal 
surveillance in 37 hospitals (Table 1).
After exclusion of recurrent episodes, the incidence 
rate of healthcare-associated CDI by hospital ranged 
from 4.2 to 131.8 per 10,000 hospital discharges 
(median: 16.4; IQR: 10.1–29.5) and from 0.6 to 18.5 
per 10,000 patient-days (median: 3.7; IQR: 2.0–6.6). 
The incidence rate of recurrent CDI varied between 0 
and 118.6 per 10,000 hospital discharges (median: 
2.0; IQR: 0.2–5.2) and between 0 and 9.0 per 10,000 
patient-days (median: 0.3; IQR: 0.04–1.2).
Light surveillance: patient characteristics and 
diagnostics
Patient data were submitted for 1,078 CDI episodes in 
37 hospitals (Figure 1). Most CDI cases were diagnosed 
by toxin enzyme immunoassay (EIA), confirmed by toxi-
genic culture (n = 220) or toxin EIA alone (n = 188). Other 
cases were diagnosed by GDH detection and confirmed 
by toxin PCR (n = 101) or toxin EIA (n = 88), by toxin PCR 
alone (n = 91), toxin PCR and toxigenic culture (n = 72) or 
other diagnostic algorithms (n = 318).
The median age of patients was 72 years (IQR: 59–80); 
38 (4%) CDI episodes were in those younger than 18 
years, of whom 13 were younger than two years. The 
current hospital was reported as being the origin of 
infection for 66% (n = 673), another hospital for 18% 
Table 1
Results from ‘minimal’ surveillancea of Clostridium difficile infection in 37 acute care hospitals in 14 European countries, 13 
May–1 November 2013b
Country  
(number of 
hospitals)
Hospital 
discharges 
n
Patient- 
days 
n
CDI 
episodes 
included 
n
HA-CDIs 
n (%)
CA-CDIs  
and CDIs of 
unknown origin 
n (%)
Recurrent 
CDIs 
n (%)
Median incidence rate of HA-CDI
per 10,000 
hospital 
discharges 
(range)
per 10,000 
patient-days 
(range)
Austria (4) 56,773 307,721 117 88 (75) 16 (14) 13 (11) 15.8 (10.0–35.4) 3.2 (2.0–4.8)
Belgium (3) 20,434 140,603 53 32 (60) 13 (25) 8 (15) 17.7 (6.0–26.6) 2.7 (0.8–3.7)
Denmark (4) 60,572 182,888 171 120 (70) 25 (15) 26 (15) 17.7 (11.0–31.0) 5.3 (4.6–11.0)
Estonia (2) 18,293 133,790 18 16 (89) 1 (6) 1 (6) 8.6 (7.3–10.0) 1.2 (0.8–1.7)
Finland (3) 10,876 39,816 29 17 (59) 9 (31) 3 (10) 14.9 (12.2–20.8) 4.4 (2.6–6.5)
France (2) 9,608 64,203 46 31 (67) 9 (20) 6 (13) 26.7 (9.1–44.3) 3.8 (2.0–5.7)
Germany (3) 66,952 307,791 174 136 (78) 33 (19) 5 (3) 23.1 (16.2–28.2) 3.6 (3.4–6.7)
Hungary (2) 18,207 166,926 254 213 (84) 24 (9) 17 (7) 121.6 (111.5–131.8) 14.9 (11.2–18.5)
Netherlands 
(3) 20,388 123,507 43 29 (67) 11 (26) 3 (7) 10.5 (10.2–19.4) 1.9 (1.8–2.9)
Norway (2) 35,365 194,204 60 33 (55) 15 (25) 12 (20) 9.6 (8.5–10.8) 1.9 (1.4–2.5)
Poland (2) 15,182 86,771 69 65 (94) 4 (6) 0 (0) 42.6 (40.7–44.6) 7.6 (7.0–8.2)
Romania (2) 19,243 90,582 33 19 (58) 7 (21) 7 (21) 12.1 (8.0–16.5) 6.7 (1.4–12.0)
Serbia (3) 8,930 59,435 49 37 (76) 2 (4) 10 (20) 89.8 (22.0–131.8) 10.0 (3.9–11.3)
UK-Scotland 
(2) 26,554 94,942 36 16 (44) 13 (36) 7 (19) 5.3 (4.2–6.4) 1.4 (0.6–2.2)
Total (37) 387,377 1,993,179 1,152 852 (74) 182 (16) 118 (10) 16.4 (4.2–131.8) 3.7 (0.6–18.5) 
CA: community-associated; CDI: Clostridium difficile infection; HA: healthcare-associated; UK-Scotland: United Kingdom (Scotland only). 
The pilot study was based on a non-representative sample, thus the results presented cannot be interpreted as being representative of any 
participating country or of the European Union/European Economic Area.
a The ‘minimal’ surveillance option comprised aggregated hospital data.
b Three-month assessment during this time period.
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Table 2
Patient characteristics from ‘light’ (n = 1,078) and ‘enhanced’ surveillancea (n = 300) of Clostridium difficile infection in 
participating acute care hospitals in selected European countriesb, with putative determinants of a complicated course of 
infection and all-cause in-hospital mortality, 13 May–1 November 2013c
Patient characteristics
Light 
surveillance 
nd/N (%)
Enhanced 
surveillance 
nd/N (%)
Univariable analysis
Complicated course 
OR (95% CI)
In-hospital mortality 
OR (95% CI)
Age in years 
< 65 370/1,077 (34) 104/299 (35) ref. ref.
65–84 549/1,077 (51) 152/299 (51) 3.4 (1.0–12.2) 1.6 (0.7–3.7)
≥ 85 158/1,077 (15) 43/299 (14) 6.6 (1.6–26.9) 2.1 (0.7–5.9)
Sex 
Female 573/1,078 (53) 157/300 (52) ref. ref.
Male 505/1,078 (47) 143/300 (48) 0.8 (0.3–1.8) 1.0 (0.5–2.1)
Recurrent infection 
No 862/978 (88) 240/277 (87) ref. ref.
Yes 116/978 (12) 37/277 (13) 0.7 (0.1–3.0) 0.9 (0.3–2.7)
CDI at admission 
No 505/984 (51) 153/276 (55) ref. ref.
Yes 479/984 (49) 123/276 (45) 1.7 (0.7–4.2) 0.3 (0.1–0.7)
Days of hospital stay to hospital-onset CDI 
Number (IQR) 11 (IQR: 6–21) 9 (IQR: 6–17) NA NA 
CDI origin 
HA 885/1,078 (82) 249/300 (83) ref. ref.
CA 131/1,078 (12) 37/300 (12) 1.0 (0.3–3.7) 0.4 (0.1–1.6)
Unknown 62/1,078 (6) 14/300 (5) 2.0 (0.4–9.4) 1.1 (0.2–5.1)
Ward speciality 
Medicale NC 194/299 (65) ref. ref.
Surgical NC 53/299 (18) 0.9 (0.3–2.8) 0.8 (0.3–2.3)
ICU NC 29/299 (10) 1.8 (0.6–5.8) 2.5 (1.0–6.5)
Other NC 23/299 (8) NA 0.7 (0.2–3.4)
Healthcare admission < 3 months 
No NC 84/287 (29) ref. ref.
Hospital NC 194/287 (68) 1.0 (0.4–2.5) 1.3 (0.6–2.9)
Other NC 9/287 (3) 1.6 (0.2–14.5) 1.0 (0.1–9.3)
Antibiotic treatment < 3 monthsf 
No NC 34/254 (13) ref. ref.
One course NC 111/254 (44) 1.4 (0.4–5.2) 1.3 (0.4–4.1)
Multiple courses NC 109/254 (43) 0.7 (0.2–3.0) 1.0 (0.3–3.3)
Expected survival in years (McCabe score) 
> 5 NC 171/285 (60) ref. ref.
1–4 NC 83/285 (29) 2.2 (0.9–5.5) 1.8 (0.7–4.5)
< 1 NC 31/285 (11) 2.5 (0.7–8.7) 12.0 (4.7–30.5)
Severe comorbidity (APACHE II CHP)g 
Liver cirrhosis NC 16/295 (5) 0.7 (0.1–5.8) 1.7 (0.5–6.1)
NYHA class IV heart failure NC 29/295 (10) 2.2 (0.7–7.0) 3.4 (1.4–8.3)
Pulmonary disease NC 38/297 (13) 3.3 (1.2–8.5) 1.7 (0.7–4.3)
Chronic dialysis NC 18/299 (6) 1.4 (0.3–6.7) 2.2 (0.7–7.2)
Immunocompromised status NC 92/291 (32) 0.8 (0.3–2.2) 1.3 (0.6–2.7)
C. difficile clade 
Clade 1, 3, 4 and 5 NC 187/267 (70) ref. ref.
Clade 2 (ribotype 027/176) NC 80/267 (30) 0.9 (0.4–2.5) 1.0 (0.4–2.3)
C. difficile binary toxin genes 
No NC 165/264 (63) ref. ref.
Yes NC 99/264 (38) 0.8 (0.3–2.1) 1.0 (0.4–2.1)
APACHE II CHP: Acute Physiology and Chronic Health Evaluation II chronic health points; CA: community-associated; CDI: Clostridium difficile infection; HA: healthcare-associated; 
ICU: intensive-care unit; IQR: interquartile range; NA: not applicable; NC: not collected; NYHA: New York Heart Association; OR: odds ratio; ref.: reference group.
a The ‘light’ surveillance option included patient data for CDI cases; in the ‘enhanced’ option, microbiological data on the first 10 CDI episodes per hospital were included.
b All 37 hospitals in 14 European countries (Austria, Belgium, Denmark, Estonia, Finland, France, Germany, Hungary, the Netherlands, Norway, Poland, Romania, Serbia and 
United Kingdom (Scotland only)) tested the light option; 32 hospitals in 13 countries (Austria, Belgium, Denmark, Finland, France, Germany, Hungary, the Netherlands, Norway, 
Poland, Romania, Serbia and United Kingdom (Scotland only)) tested the enhanced option.
c Three-month assessment during this time period.
d Number of episodes/total number of episodes for which data were available, unless otherwise indicated.
e ‘Medical’ included several subspecialties of internal medicine (see protocol [14]).
f Antibiotic treatment in past 3 months was the only variable with > 10% missing data.
g The reference group consisted of patients without the comorbidity listed.
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Table 3
Surveillance indicators used to evaluate the ability to collect data and workload for the three surveillance optionsa for 
Clostridium difficile infection in 37 acute care hospitals in 14 European countriesb, 13 May–1 November 2013c
Country 
(number of 
hospitals 
in light/
enhanced 
surveillance)
Surveillance option
Minimal Light Enhanced 
Testing 
frequency
Proportion 
of positive 
tests
Workload
Patient  
data 
availablef
Data on  
CDI origin Workload
Data 
on CDI 
outcomeg
Matching 
PCR 
ribotypeh
Workload
Median 
number of 
tests per 
10,000 
patient 
daysd 
(range)
n/N (%)
Median 
number of 
person-days 
per 10,000 
hospital 
dischargese 
(range)
n/N (%) n/N (%)
Median 
number of 
person-days 
per 10,000 
hospital 
dischargese 
(range)
n/N (%) n/N (%)
Median 
number of 
person-days 
per 10,000 
hospital 
dischargese 
(range) 
Austria (4/4) 31 (21–66) 111/1,117 (10) 0.7 (0.1–2.1) 111/117  (95)
109/111  
(98) 2.1 (0.5–10.3)
40/40  
(100)
26/34 
(76) 2.8 (1.0–3.0)
Belgium (3/3) 55 (50–85) 60/833  (7) 0.3 (0.1–0.8)
53/53  
(100)
52/53  
(98) 1.6 (1.5–2.2)
26/28  
(93)
16/26 
(62) 1.6 (0.8–4.4)
Denmark 
(4/4)
71 
(43–105)
202/1,360 
(15) 0.5 (0.3–0.9)
168/171  
(98)
163/168  
(97) 1.0 (0.9–2.0)
37/39  
(95) NA 1.7 (1.3–2.5)
Estonia (2/0)i 17 (10–24) 17/218  (8) NA
17/18  
(94)
17/17  
(100) NA NA NA NA
Finland (3/1) 129 (33–151)
48/448  
(11) 1.2 (0.8–4.2)
23/29  
(79)
23/23  
(100) 3.3 (1.2–4.2)
10/10  
(100)
9/10  
(90) 5.0
j 
France (2/1) 72 (63–81) 35/493  (7) NA
40/46 
(87)
39/40  
(98) NA
10/10  
(100)
5/9  
(56) NA
Germany 
(3/3) 82 (70–111)
174/2,656  
(7) 1.0 (0.1–1.8)
171/174  
(98)
153/171  
(89) 1.2 (0.5–1.8)
30/30  
(100)
21/27 
(78) 2.1 (1.2–3.0)
Hungary (2/2) 77 (67–86) 237/1,192 (20) 2.5 (2.0–3.0)
251/254  
(99)
236/251  
(94)
38.7 
(28.4–49.0)
19/20  
(95)
14/17 
(82) 9.6 (4.1–15.1)
Netherlands 
(3/3) 45 (7–262)
79/1,124  
(7) 1.7 (0.6–1.8) 43/43 (100)
38/43  
(88) 1.8 (1.7–5.1)
29/29  
(100) NA 5.3 (4.0–13.6)
Norway (2/2)i 38 (23–52) 60/614  (10) 0.8
j 60/60 (100) 55/60  (92) 1.5
j 20/20  
(100)
12/18 
(67) 2.3
j
Poland (2/2)i 20 (18–21) 79/173  (46) NA 34/69 (49)
34/34  
(100) NA
19/19  
(100)
16/16 
(100) NA
Romania 
(2/2)i
308 
(9–607)
26/427  
(6) NA 26/33 (79)
24/26  
(92) NA
12/13  
(92) NA NA
Serbia (3/3)i 40 (7–184) 49/253  (19)
15.0 
(2.9–26.4) 49/49 (100)
49/49  
(100)
15.0 
(2.9–26.4)
30/30  
(100) NA
37.4 
(5.9–92.2)
UK-Scotland 
(2/2)
179 
(142–216)
33/1,813  
(2) 2.2 (2.1–2.3) 32/36 (89)
24/32  
(75) 4.7 (2.1–7.3)
12/12  
(100)
9/9  
(100) 3.7 (1.2–6.3)
Total (37/32) 58 (7–607) 1,210/12,721  (10) 1.1 (0.1–26.4) 
1,078/1,152 
(94) 
1,016/1,078 
(94) 2.0 (0.5–49.0)
294/300 
(98) 
128/166 
(77) 
3.0 
(0.8–92.2) 
CDI: Clostridium difficile infection; NA: not available; UK-Scotland: United Kingdom (Scotland only).
The pilot study was based on a non-representative sample, thus the results presented in this table cannot be interpreted as being 
representative of any participating country or of the European Union/European Economic Area. 
Missing values indicate that hospitals did not participate in enhanced surveillance and/or did not reply to the feasibility questionnaire.
a Three surveillance options were tested: ‘minimal’ (aggregated hospital data), ‘light’ (including patient data for CDI cases) and ‘enhanced’ 
(including microbiological data on the first 10 CDI episodes per hospital).
b Austria, Belgium, Denmark, Estonia, Finland, France, Germany, Hungary, the Netherlands, Norway, Poland, Romania, Serbia, United Kingdom 
(Scotland only) carried out minimal and light surveillance. Austria, Belgium, Denmark, Finland, France, Germany, Hungary, the Netherlands, 
Norway, Poland, Romania, Serbia and United Kingdom (Scotland only) also carried out enhanced surveillance.
c Three-month assessment during this time period.
d Median testing of the country’s participating hospitals.
e Workload needed to complete the surveillance option, as reported by 26 respondents who completed the feasibility questionnaire. 
f Number of patients with clinical data available, divided by the number of patients reported by minimal surveillance, expressed as a 
percentage. 
g Percentage of patients for whom the presence or absence of a complicated in-hospital outcome (as defined in the Box) was identified. 
h Percentage of isolates of which the reported ribotype matched the results of the coordinating laboratory.
i Countries without an implemented national surveillance of CDI at the start of the European Clostridium difficile Infection Surveillance 
Network (ECDIS-Net) project.
j One hospital provided a response to this question, therefore no range was calculable.
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(n = 178), a long-term care facility for 1% (n = 13) and 
another healthcare facility for 2% (n = 21) of the 1,016 
CDI episodes of known origin (for 62 episodes, the ori-
gin was unknown). Other patient characteristics are 
shown in Table 2.
Enhanced surveillance: complicated CDI and in-hospital 
mortality
For 300 CDI episodes in 32 hospitals, enhanced sur-
veillance data were also submitted (Table 2). The 
course of CDI was known for 98% (n = 294) of cases; 
8% (n = 24) experienced a complicated course of infec-
tion (as defined in the Box). In univariable analysis, 
a complicated course was associated with age of 85 
years or older and severe pulmonary disease, but not 
with CDI origin, presence of PCR ribotypes 027 or 176, 
or of binary toxin genes (Table 2). A total of 12% (n = 37) 
of CDI cases died during hospitalisation. Six deaths 
(2% of all CDI episodes) were related to CDI, 23 deaths 
(8% of all CDI episodes) were unrelated to CDI, and the 
relationship between CDI and death was unknown for 
the remaining eight episodes (3% of all CDI episodes). 
Patients with a complicated course had a 42% risk of 
in-hospital death (of which 25% were CDI-related) com-
pared with 9% among patients with an uncomplicated 
course. All-cause in-hospital mortality was associated 
with a lower number of years of expected survival (a 
high McCabe score), healthcare-onset CDI and severe 
heart failure, but not with CDI origin, presence of PCR 
ribotypes 027 or 176, or of binary toxin genes (Table 2). 
Enhanced surveillance: microbiological data
C. difficile was cultured and characterised in the coor-
dinating laboratory for 267 (89%) of the 300 CDI epi-
sodes registered during enhanced surveillance. The 
presence of toxin A and B genes was confirmed in 99% 
(263/265) of the cultured isolates; binary toxin genes 
were present in 38% (99/264) of the isolates. A total 
of 51 different PCR ribotypes were characterised. The 
predominant PCR ribotype was 027 (30%; n = 79), fol-
lowed by the highly related PCR ribotypes 014 and 
020 (15%; n = 40), and PCR ribotype 001 (6%; n = 15). 
PCR ribotype 027 was identified in isolates from eight 
European countries in 4–85% of all characterised sam-
ples, depending on the country (Figure 2).
PCR ribotype 176, which is highly related to 027, was 
found in one CDI case in a country where no PCR 
ribotype 027 isolates were identified. The proportion of 
PCR ribotype 027 isolates correlated with the incidence 
rate of HA-CDI per 10,000 patient-days (Spearman’s 
rho: 0.64; 95% CI: 0.36–0.81) (Figure 3).
All isolates that were investigated for antimicrobial sus-
ceptibility (n = 251) were susceptible in vitro to metroni-
dazole. Eight PCR ribotype 027 isolates from Austria, 
Germany and Hungary showed reduced susceptibility 
to metronidazole, with a MIC just below the EUCAST 
epidemiological cut-off value [24]. Two PCR ribotype 
027 isolates from Denmark showed reduced suscepti-
bility to vancomycin, with a MIC just below the EUCAST 
epidemiological cut-off value [24]; however, resistance 
to vancomycin was not detected. In vitro moxifloxacin 
resistance was identified in 37% (n = 92) isolates, of 
which 77% (n = 71) belonged to PCR ribotype 027.
Feasibility and workload
Participating hospitals reported a median of seven CDI 
episodes (IQR: 4–12) per month through both minimal 
and light surveillance. The feasibility questionnaire 
was completed by 26 of the 37 participating hospitals. 
Completion of the light and enhanced options were 
found to be ‘not difficult’ for 23/26 and 21/24 respond-
ents, respectively. The remaining respondents found 
them ‘quite difficult’.
The median workload for the ‘minimal’, ‘light’ and 
‘enhanced’ surveillance options was 1.1, 2.0 and 3.0 
person-days per 10,000 hospital discharges, respec-
tively (Table 3).
The highest workload was reported by countries with 
the highest aggregated CDI incidence rates during the 
pilot (Serbia and Hungary). There were no differences 
in surveillance indicators by pre-existing surveillance 
activities, or when considering laboratory or typing 
capacity for CDI in the pilot study (Table 3).
Data quality
Completeness of data was 94% (1,078/1,152) for patient 
data in the light option and 98% (294/300) for data on 
the course of CDI in the enhanced option. Testing fre-
quency (range: 17–308 tests per 10,000 patient days) 
and the proportion of positive tests (range: 2–46%) 
varied between countries (Table 3). The testing fre-
quency correlated with the overall CDI incidence rate 
per 10,000 patient days (Spearman’s rho: 0.45; 95% 
CI: 0.15–0.68). PCR ribotyping results from the NRLs 
obtained during enhanced surveillance were concord-
ant with the coordinating laboratory’s results for 77% 
(128/166) of the isolates. Discordant results were either 
due to a mismatch in the identified PCR ribotype (n = 19; 
11%), or because a PCR ribotype pattern result was not 
recognised by a NRL (n = 17; 10%) or by the coordinat-
ing laboratory (n = 2; 1%). External quality assessment 
demonstrated 75% and 86% accuracy of PCR ribotype 
allocation by the NRLs in 2013 and 2014, respectively.
Discussion
CDIs are a major concern for hospitals in Europe. The 
first ECDC point prevalence survey in 2011–12 estimated 
that 123,997 patients (95% CI: 107,697–441,969) devel-
oped a HA-CDI within the European Union each year [9]. 
In the United States, CDI has been declared an ‘urgent 
threat’ [25], with an estimated 80,400 HA-CDI cases 
in 2011 [26]. Establishing Europe-wide surveillance of 
CDIs is a pre-requisite to controlling these infections 
in Europe. In 2011, 14 European countries had national 
CDI surveillance, but methodologies varied, and only 
four countries regularly linked C. difficile microbio-
logical results to epidemiological data [3]. Therefore, 
a standardised protocol was proposed for periodical 
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or continuous CDI surveillance in European acute care 
hospitals, allowing direct interhospital and intercoun-
try comparison of surveillance results.
Feasibility
Results of our study in which we piloted a standard-
ised surveillance protocol for CDI for European acute 
care hospitals suggests that all three surveillance 
options were manageable in participating countries, 
regardless of the countries’ pre-established level of 
CDI surveillance and microbiological typing capacity. 
Completeness of data was high, and hospital partici-
pants reported that the workload was manageable. 
Nevertheless, modifications were made on the surveil-
lance methodology and forms to further optimise data 
collection. The finalised protocol version 2.2 is now 
available on the website of ECDC [27].
Epidemiological and microbiological findings
Using the pilot protocol, participating hospitals could 
obtain detailed information on the local epidemiology 
of CDI at their respective facilities that could be used 
to target and reinforce infection prevention and control 
measures and resources. This pilot study had an impor-
tant impact on certain national CDI-related activities as 
well: three of five participating countries that did not 
have national CDI surveillance at start of the ECDIS-
Net project reported a high percentage of PCR ribotype 
027 isolates in this study, and two of these countries 
(Poland [28] and Romania) decided to continue with 
intensified CDI surveillance. Interest in the surveillance 
and completeness of results also suggests that wide-
scale implementation at national and European level 
would be successful in acute care hospitals.
Although the non-representative selection of hospitals 
does not allow for interhospital or intercountry com-
parisons in the pilot study, patients enrolled in the 
enhanced option permitted a more in-depth analysis of 
the pilot data collected, allowing us to assess the rela-
tionship between patient and microbiological charac-
teristics and in-hospital outcome of CDI, our secondary 
objective. Similar to the findings of a European study 
performed in 2008 [2], the majority of the patients in 
our pilot study had risk factors for CDI (e.g. median age 
of 72 years and 87% had used antibiotics in the pre-
vious three months). We found plausible associations 
between certain comorbidity variables and a compli-
cated course of CDI or all-cause in-hospital mortality 
of CDI cases; however, the presence of PCR ribotypes 
027 and 176 was not associated with a higher risk of 
all-cause in-hospital death, as found in a larger study 
in the United Kingdom in 2006–11 [29]. In contrast, the 
proportion of PCR ribotypes 027 isolates correlated 
with a higher incidence rate of HA-CDI, thus corrobo-
rating existing evidence on the high potential of this C. 
difficile PCR ribotype to spread. Indeed, this fluoroqui-
nolone-resistant strain that emerged in Europe in 2004 
[13] was the most frequently isolated ribotype, par-
ticularly in participating hospitals of eastern European 
countries. This finding is in line with the ‘European, 
multicentre, prospective, biannual, point-prevalence 
study of C. difficile infection in patients admitted 
with diarrhoea’ (EUCLID) study (2011–13) that found 
PCR ribotype 027 to be most prevalent, clustering in 
Germany, Hungary, Poland and Romania [12].
Resistance to antibiotics that are routinely used to treat 
CDIs such as metronidazole and vancomycin was not 
detected in our study. Two PCR ribotype 027 isolates 
from one hospital showed a decreased susceptibility to 
vancomycin (MIC = 2 mg/L), but the clinical relevance of 
this finding is uncertain.
Data quality
We found varying frequencies of testing for CDI and 
percentages of positive tests in participating hospi-
tals and countries, primarily indicating the need for 
an update of the European diagnostic guideline [30] 
and for promotion of optimal ascertainment of CDI. In 
addition, there is a need to address local or national 
variations in CDI case finding, ascertainment and 
reporting, which may be substantial across Europe, 
due to probable differences in clinical and laboratory 
awareness, practices of specimen collection from diar-
rhoeic patients and specimen transport, clinical and 
laboratory indications, requests from physicians and 
CDI testing methods, local epidemiology (e.g. intensi-
fied testing during outbreaks), financial resources to 
test for CDI, data sources for surveillance, and report-
ing incentives or disincentives. Therefore, we suggest 
that in CDI surveillance programmes the possibility of 
adjusting CDI incidence rates at least for key factors 
related to sampling and testing methods should be 
investigated. We recommend that validation studies 
accompany national surveillance to estimate sensi-
tivity and specificity, in order to correct national and 
European CDI infection rate estimates.
Furthermore, standardisation of PCR ribotyping is 
essential for implementation of the enhanced surveil-
lance option, as results show suboptimal concordance 
between results of national and external laboratories. 
Agarose-based ribotyping results are more difficult to 
interpret and to exchange between laboratories than 
capillary-based results [31]. The increase, from 23% in 
2011 to 50% in 2014, in the percentage of ECDIS-Net 
participating countries that use capillary-based PCR 
ribotyping [18] was the most likely explanation for 
the better performance in the external quality control 
exercise in 2014 [31]. Further standardisation of PCR 
ribotyping will likely be achieved by regular exchange 
of new C. difficile strains and build-up of a consistent 
reference database. The first steps have already been 
taken by concerted action of ECDIS-Net members with 
reference laboratories from CDC and the Public Health 
Agency of Canada [31]. At the same time, new develop-
ments in DNA sequence analyses should be monitored 
closely for application in ribotyping modifications and 
considered for implementation in surveillance activi-
ties of C. difficile [32]. In our pilot study, PCR ribotyp-
ing of the first 10 strains per hospital in the enhanced 
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option was performed to balance effort, costs and ben-
efits, such as in the national surveillance programme 
of Belgium [5]. Despite these positive experiences, fur-
ther evidence for this approach should be obtained and 
evaluated at European level.
Other limitations
The results of our pilot study are not generalisable 
to all European acute care hospitals as it was based 
on a non-representative convenience sample, as also 
indicated by the disproportionally high number of ter-
tiary care hospitals (21/37) in our sample. Similarly, 
our analytical epidemiological results and country-
specific results are based on very small numbers of 
hospitals and should not be considered as representa-
tive. Specifically, the number of events allowed for 
univariable analysis only when exploring associations 
between covariables and outcome of CDI. Assessing 
the local context in more details (e.g. gathering infor-
mation on clinical practices and/or policies related to 
specimen collection and CDI testing in the participat-
ing hospitals) or covering all CDC surveillance evalua-
tion attributes [33] was beyond the scope of this pilot 
study. Local audits to determine surveillance sensitiv-
ity, in both case finding and collection of denominator 
data, could have helped to elucidate some of the larger 
observed variations.
Conclusions
We conclude that continuous or periodical surveillance 
with collection of different levels of epidemiological 
and microbiological data following a standardised pro-
tocol is a feasible strategy to monitor CDIs in European 
acute care hospitals. Ideally, national and international 
validation studies, regular and comprehensive evalua-
tion of the surveillance protocol, as well as CDI case 
finding, ascertainment and reporting should comple-
ment the surveillance activity.
ECDC has used the final protocol version 2.2 to initi-
ate CDI surveillance in EU/EEA countries in 2016, and 
will gradually incorporate enhanced surveillance data 
in The European Surveillance System (TESSy) [27,34]. 
Importantly, the surveillance of CDI in European acute 
care hospitals will be the first Europe-wide, hospital-
based surveillance of a primarily healthcare-associated 
infection with a distinct microbiological component. 
The protocol can be used as a tool to guide local CDI 
surveillance and ultimately contribute to reducing CDI 
incidence rates in acute care hospitals. Finally, aggre-
gated data from nationally representative samples 
should allow an estimation of the true incidence rate 
of CDIs in Europe.
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